Clinical Characteristics, Prognostic Factors, and Thrombotic and Bleeding Outcomes in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Single-Center Cohort Study in Thailand
Open Access
- 12 April 2025
- journal article
- Published by Springer Nature in Cureus
- Vol. 17 (4) , e82141
Abstract
Background Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), face elevated risks of thrombosis and major bleeding. Because of these potentially severe complications, antiplatelet and anticoagulant therapies are often employed. This study aimed to evaluate thrombotic and bleeding events, identify associated risk factors, assess prognostic risk models, and investigate the effects of antithrombotic therapy in a Thai cohort of patients with Ph-neg MPNs. Methods This single-center cohort study in Thailand enrolled patients with Ph-neg MPNs from 2013 to 2023. Clinical characteristics, prognostic risk models (International Prognostic Scoring System (IPSS), International Prognostic Score for Essential Thrombocythemia (IPSET)-thrombosis, and Dynamic International Prognostic Scoring System (DIPSS)), and arterial and venous thrombotic events and bleeding complications were analyzed using descriptive statistics, logistic regression, and survival analysis. Results Among 173 patients, PV was the most common subtype (n = 111, 64.2%), with a male predominance and a median age of 57 years. Thrombotic events occurred in 36.9% (n = 41) of PV, 21.4% (n = 3) of PMF, and 18.8% (n = 9) of ET cases, with arterial thrombosis, particularly ischemic stroke, being the most frequent. The JAK2V617F mutation was prevalent in 72.5% (n = 79) of PV, 70.8% (n = 34) of ET, and 50% (n = 5) of PMF patients. Notably, no major bleeding events were observed despite intensive antithrombotic therapy. Multivariable analysis revealed that prior ischemic stroke (OR 22.51, P = 0.007) and dizziness/headache (OR 7.26, P = 0.022) were significant risk factors for thrombosis. Overall survival (OS) varied by disease subtype. PV patients had a five-year OS of 94.9% and a 10-year OS of 87.2%. ET patients demonstrated a five-year OS of 77.4%. PMF patients had the lowest survival, with a five-year OS of 67.7%. Conclusions This cohort study offers important insights into the clinical characteristics and complication profiles of Ph-neg MPNs in a Thai population. Compared with Western cohorts, patients in this study exhibited a higher incidence of thrombotic events, particularly ischemic stroke. These findings emphasize the need to consider regional variations in disease presentation and underscore the value of individualized risk stratification to optimize patient management in diverse clinical settings.Keywords
This publication has 39 references indexed in Scilit:
- Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendationsThe Lancet Haematology, 2022
- Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative NeoplasmsHematology/Oncology Clinics of North America, 2021
- Thrombosis among 1537 patients with JAK2V617F‐mutated myeloproliferative neoplasms: Risk factors and development of a predictive modelCancer Medicine, 2020
- Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk‐stratification and managementAmerican Journal of Hematology, 2018
- Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burdenThrombosis Research, 2015
- JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in JapanInternational Journal of Hematology, 2014
- Are MPNs Vascular Diseases?Current Hematologic Malignancy Reports, 2013
- Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2012
- Transfusion‐dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis—prognostic relevance is independent of IPSS or karyotypeAmerican Journal of Hematology, 2009
- Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disordersLeukemia, 2008